Please ensure Javascript is enabled for purposes of website accessibility

Why Cassava Sciences Stock Skyrocketed Today

By Joe Tenebruso - Feb 2, 2021 at 5:49PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech's experimental Alzheimer's treatment could be a game changer.

What happened

Shares of Cassava Sciences (SAVA 4.88%) soared 141% on Tuesday after the biotechnology company released promising data from a study evaluating simufilam, its drug candidate for the treatment of Alzheimer's disease. 

So what

An interim analysis of Cassava's clinical study showed an improvement in patients' cognition function following six months of simufilam treatment. Study participants' cognition scores improved by 10% on average from baseline. Better still, these patients' dementia-related symptoms, such as anxiety and agitation, improved by an average of 29% from baseline.

Importantly, no serious safety issues were reported during the study.

An upwardly sloping stock chart

Shares of Cassava Sciences surged on Tuesday. Image source: Getty Images.

The results were particularly impressive, as Alzheimer's is a progressive disease that causes the cognitive abilities of those who suffer from it to decline over time.

"We would have been satisfied to show simufilam stabilizes cognition in patients over 6 months," CEO Remi Barbier said in a press release. "An improvement in cognition and behavior tells us this drug candidate has potential to provide lasting treatment effects for people living with Alzheimer's disease."

Now what

Cassava Sciences intends to begin a phase 3 clinical trial of simufilam in the second half of 2021. Should the treatment continue to show the ability to safely improve cognition function in people with Alzheimer's, its market potential would likely be enormous. Nearly 6 million people in the U.S. alone suffer from the memory-destroying disease, and there are currently no drugs on the market that can halt its progression.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Cassava Sciences, Inc. Stock Quote
Cassava Sciences, Inc.
SAVA
$25.15 (4.88%) $1.17

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/22/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.